• Percentage of time spent in sensor glucose target range defined as between 3.9 and 7.8 mmol/L compared between 4- weeks AP on empagliflozin and 4-weeks AP with placebo [ Time Frame: 20 weeks ]
  Percentage of time spent in sensor glucose target range defined as between 3.9 and 7.8 mmol/L compared between 4- weeks AP on empagliflozin and 4-weeks AP with placebo.
• Percentage of time spent in sensor glucose target range defined as between 3.9 and 7.8 mmol/L compared between 4- weeks conventional pump therapy on empagliflozin and 4- weeks conventional pump therapy with placebo [ Time Frame: 20 weeks ]
  Percentage of time spent in sensor glucose target range defined as between 3.9 and 7.8 mmol/L compared between 4- weeks conventional pump therapy on empagliflozin and 4- weeks conventional pump therapy with placebo.
• Percentage of time spent in sensor glucose target range defined as between 3.9 and 7.8 mmol/L on 4- weeks automated AP on empagliflozin when compared to 4-weeks conventional pump therapy on empagliflozin [ Time Frame: 20 weeks ]
  Percentage of time spent in sensor glucose target range defined as between 3.9 and 7.8 mmol/L on 4- weeks automated AP on empagliflozin when compared to 4-weeks conventional pump therapy on empagliflozin.
• Percentage of time spent in sensor glucose target range defined as between 3.9 and 7.8 mmol/L on 4- weeks automated AP on empagliflozin when compared to 4-weeks conventional pump therapy with placebo [ Time Frame: 20 weeks ]
  Percentage of time spent in sensor glucose target range defined as between 3.9 and 7.8 mmol/L on 4- weeks automated AP on empagliflozin when compared to 4-weeks conventional pump therapy with placebo.

• Percentage of time spent in sensor glucose target range defined as between 3.9 and 10.0 mmol/L compared between 4- weeks conventional pump therapy on empagliflozin and 4-weeks AP on empagliflozin [ Time Frame: 20 weeks ]
  Percentage of time spent in sensor glucose target range defined as between 3.9 and 10.0 mmol/L compared between 4- weeks conventional pump therapy on empagliflozin and 4-weeks AP on empagliflozin
• Percentage of time spent in sensor glucose target range defined as between 3.9 and 10.0 mmol/L compared between 4- weeks AP on empagliflozin and 4- weeks AP with placebo [ Time Frame: 20 weeks ]
  Percentage of time spent in sensor glucose target range defined as between 3.9 and 10.0 mmol/L compared between 4- weeks AP on empagliflozin and 4- weeks AP with placebo.
• Hypoglycemia: Percentage of time with glucose <3.9 mmol/L applied to each of the primary and secondary outcome comparator groups [ Time Frame: 20 weeks ]
  Hypoglycemia: Percentage of time with glucose <3.9 mmol/L applied to each of the primary and secondary outcome comparator groups.
• Percentage of time spent in hypoglycemia, euglycemia and hyperglycemia [ Time Frame: 20 weeks ]
  Percentage of time spent in the different glucose sensor levels characterized by amount spent between 3.9 and 10.0 mmol/L, 3.9 and 7.8 mmol/L, above 10.0 mmol/L, above 13.9 mmol/L, above 16.7 mmol/l, below 3.9 mmol/L, below 3.3 mmol/L, below 2.8 mmol/L
• Absolute number of hypoglycemia events I. [ Time Frame: 20 weeks ]
  Number of hypoglycemic events (> 20 minutes) below 3.3 mmol/L based on sensor glucose levels
• Absolute number of hypoglycemia events II. [ Time Frame: 20 weeks ]
  Number of symptomatic hypoglycemic events < 3.9 mmol/l or below 3.3 mmol/l without symptoms
• Absolute number of hypoglycemia events III. [ Time Frame: 20 weeks ]
  Number of treated hypoglycemic events
• Statistical characteristics of glucose profile I. [ Time Frame: 20 weeks ]
  Area under the curve of hypoglycemic glucose values (below 3.9 mmol/L, 3.3 mmol/L and 2.8 mmol/L)
• Statistical characteristics of glucose profile II. [ Time Frame: 20 weeks ]
  Standard deviation of glucose levels
• Amount of total insulin delivery during interventions [ Time Frame: 20 weeks ]
  Total insulin delivery measured by mean of units per day
• Change in HbA1c [ Time Frame: 20 weeks ]
  Change in HbA1c from baseline to after the first intervention and from the end of the first intervention to the end of the treatment period.
• Mean fasting capillary ketone levels [ Time Frame: 20 weeks ]
  Mean fasting capillary ketone levels.
• Number of episodes of diabetic ketoacidosis [ Time Frame: 20 weeks ]
  Number of episodes of diabetic ketoacidosis
• Number of technical adverse events [ Time Frame: 20 weeks ]
  Number of events when algorithm crashes or needs to be overridden for safety reasons.

• Drug: empagliflozin
  Treatment with empagliflozin 25mg orally once a day
• Device: artificial pancreas
  Insulin delivery via a closed loop single-hormone artificial pancreas system.

• Active Comparator: Empagliflozin arm

  Participant will be treated by empagliflozin for 8 weeks. During these 8 weeks he will use artificial pancreas to deliver the insulin for 4 weeks and conventional pump therapy for remaining 4 weeks, in a random order.

  After finishing the entire arm intervention participant will undergo 7 day of washout and enters the placebo arm.

  Participant and research staff is blinded to arm assignment.

  Interventions:

  • Drug: empagliflozin
  • Device: artificial pancreas
• Placebo Comparator: Placebo arm

  Participant will take placebo for 8 weeks. During these 8 weeks he will use artificial pancreas to deliver the insulin for 4 weeks and conventional pump therapy for remaining 4 weeks, in a random order.

  After finishing the entire arm intervention participant will undergo 7 day of washout and enters the empagliflozin arm.

  Participant and research staff is blinded to arm assignment.

  Intervention: Device: artificial pancreas

Inclusion Criteria:

1. Signed and dated written informed consent by the date of Visit 1 in accordance with Good Clinical Practice (GCP) and local legislation.
2. Males and females ≥ 18 years of age.
3. Clinical diagnosis of T1D for at least one year. The diagnosis of T1D is based on the investigator's clinical judgment; C peptide level and antibody determinations are not planned.
4. Insulin pump therapy use for at least 3 months.
5. HbA1c ≤ 10%.
6. eGFR ≥ 60 mL/min/1.73 m² as calculated by the CKD-EPI formula.
7. Women of child-bearing potential must be ready and able to use highly effective methods of birth control that result in a low failure rate of less than 1% per year when used consistently and correctly.

Exclusion Criteria:

1. Clinically significant nephropathy, neuropathy or retinopathy as judged by the investigator.
2. Recent (< 6 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery.
3. Renal insufficiency (characterized at eGFR below 60 mmol/l at the beginning of the trial)
4. History of pheochromocytoma or insulinoma
5. Beta-blockers at high dose (interference with glucose management).
6. Chronic acetaminophen treatment (can interfere with glucose sensor measurements).
7. Warfarin chronic treatment if INR monitoring cannot be evaluated (can increase the risk of bleeding).
8. Current use of other non-insulin adjunct anti-hyperglycemic drug or use within 30 days prior to screening.
9. Use of loop diuretics (e.g. furosemide, due to possible interference with study drug mechanism of action).
10. Ongoing or planned pregnancy or breastfeeding.
11. Severe hypoglycemic episode within one month prior to Visit 1.
12. Diabetic ketoacidosis in the last 3 months prior to Visit 1.
13. Current use of glucocorticoid medication except low stable dose and inhaled steroids (can interfere with glucose sensor measurements).
14. Known or suspected allergy to the trial products.
15. Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator.
16. Anticipating a significant change in exercise regimen between initiation of two intervention blocks (i.e. starting or stopping an organized sport).
17. Recent history of genital or urinary infection (<1 month prior to Visit 1) or history of recurrent urinary tract infections.
18. Difficulty in using the artificial pancreas system following training.